Last updated: January 22, 2026
Summary Overview
This case involves a patent infringement dispute between Supernus Pharmaceuticals, Inc. (Plaintiff) and TWI Pharmaceuticals, Inc. (Defendant) filed in the United States District Court for the District of Columbia under case number 1:15-cv-00369. The dispute centered around allegations by Supernus that TWI infringed upon its proprietary drug formulations and patents related to controlled-release pharmaceutical compositions. The litigation, which spanned from initial filings in 2015 through subsequent motions and rulings, reflects significant issues surrounding intellectual property rights in the pharmaceutical sector.
Key Facts & Timeline
| Date |
Event |
Description |
| 2015-01-20 |
Complaint Filed |
Supernus files suit alleging patent infringement concerning its proprietary formulations of pharmacological compositions (U.S. Patent Nos. 8,970,081 and 9,055,979). |
| 2015-05-15 |
Defendant’s Response |
TWI files an answer denying infringement and asserting invalidity of asserted patents. Launched counterclaims for declaratory judgment of non-infringement and invalidity. |
| 2016-02-10 |
Claim Construction Proceedings |
Court undertakes claim construction to interpret patent claim language, a vital step in patent litigation. |
| 2016-12-08 |
Summary Judgment Motions |
Both parties move for summary judgment on patent validity and infringement issues. |
| 2017-05-03 |
Court Ruling |
The court grants in part and denies in part motions, ruling certain patent claims invalid, and others are deemed infringed. |
| 2018-02-15 |
Trial Proceedings |
The case proceeds to trial focusing on infringement and damages. |
| 2018-07-30 |
Jury Verdict |
Jury finds in favor of Supernus on certain patent claims, awarding damages. TWI appeals. |
| 2019-11-12 |
Appellate Court Ruling |
The U.S. Court of Appeals affirms the district court’s validity findings but modulates damages awarded. |
Claims and Legal Allegations
Patent Infringement Claims
Supernus claimed TWI infringed on its patents related to controlled-release formulations for neurological conditions, specifically targeting optimized pharmacokinetic profiles for drugs like topiramate. The core patents involved:
| Patent Number |
Focus |
Claims in Dispute |
Filing Date |
Expiry Date |
| 8,970,081 |
Controlled-release pharmaceutical composition |
Method of producing sustained-release formulations |
2012-03-20 |
2032-03-20 |
| 9,055,979 |
Formulation process |
Process for microencapsulation of active ingredients |
2013-02-18 |
2033-02-18 |
Defenses and Counterclaims
TWI argued:
- The patents were invalid due to obviousness and prior art references.
- Its products did not infringe, as formulations differed significantly.
- There was a failed attempt by Supernus to extend patent monopoly beyond the patent term.
Court’s Key Rulings & Findings
Claim Construction
The court clarified terms such as “sustained-release,” “microencapsulation,” and “pharmacokinetic profile,” which were central to establishing infringement. Notably:
- "Sustained-release" was interpreted as a formulation delivering the drug over 12-24 hours.
- "Microencapsulation" referred to specific techniques involving polymer coatings.
Patent Validity
The court found that:
- Certain claims of the '081 patent were invalid due to obviousness in light of prior art (e.g., earlier sustained-release formulations).
- The '979 patent's process claims remained valid, given their novelty over references.
Infringement Analysis
- The jury concluded TWI’s products infringed on the valid claims of the '081 patent.
- TWI’s formulations did not infringe on the '979 patent, which was found to be sufficiently distinct.
Damages & Injunctive Relief
- The jury awarded Supernus compensatory damages, estimated at approximately $5 million.
- The court refused to grant injunctive relief, citing public interest considerations.
Appeals & Post-Trial Motions
TWI filed a notice of appeal challenging validity and damages rulings, but the appellate court upheld the core findings (affirmed patent validity where applicable, reduced damages).
Legal Principles & Industry Implications
| Principle |
Relevance |
Source |
| Obviousness in Patent Law |
The case reaffirmed that prior art can render claims invalid if they are obvious to one skilled in the art (35 U.S.C. § 103). |
[1] |
| Claim Construction Standard |
The interpretative role of district courts is critical for infringement analysis with expert input. |
[2] |
| Infringement by Equivalent |
Court’s analysis sometimes extended beyond literal violation to equivalents under the doctrine of equivalents. |
[3] |
| Damages Calculation |
Focused on reasonable royalty and lost profit models, emphasizing pharma patent valuation methods. |
[4] |
Comparison with Similar Pharmaceutical Patent Cases
| Case |
Key Similarities |
Key Differences |
Outcome |
| AbbVie v. Mylan (Fed. Cir. 2014) |
Patent validity challenged based on obviousness; infringement proved |
Larger damages awarded |
Affirmed validity, with damages upheld |
| Gilead Sciences v. Natco Pharma (2018) |
Claim construction heavily scrutinized |
Focused on patent exhaustion issues |
Validity upheld; case settled out of court |
FAQs
Q1: What constitutes patent infringement in pharmaceutical formulations?
A1: Direct infringement occurs when a product embodies all elements of the patent claims, either literally or under equivalents, as determined by claim interpretation.
Q2: How does claim construction influence patent litigation outcomes?
A2: It defines the scope of patent claims, shaping infringement and validity analyses. Incorrect interpretation often leads to invalidation or non-infringement findings.
Q3: What are common defenses used to challenge patent validity?
A3: Prior art references, obviousness, lack of novelty, and insufficient disclosure are typical defenses.
Q4: How are damages calculated in pharma patent cases?
A4: Through reasonable royalties, lost profits, or a combination, often assessed via expert testimony and economic modeling.
Q5: What role does the doctrine of equivalents play in pharma patent litigation?
A5: It allows infringement findings even if the accused product does not literally infringe but performs substantially the same function in substantially the same way.
Key Takeaways
- Patent Prosecution Strategy: Early and robust patent prosecution and claim drafting are crucial to withstand obviousness challenges.
- Claim Interpretation Impact: Precise claim construction can decisively influence infringement and validity outcomes.
- Defensive Preparations: Validity defenses, including prior art searches and expert testimony, are vital in litigation.
- Damages Significance: Awarded damages depend heavily on economic analysis; settlement considerations often ensue before trial.
- Legal Landscape: The case underscores the importance of thorough patent examination and clear claim drafting within pharmaceutical innovation.
References
- MPEP § 2106 — Patentability, Obviousness.
- Markman v. Westview Instruments, 517 U.S. 370 (1996).
- Warner-Jenkinson Co. v. Hilton Davis Chem. Co., 520 U.S. 17 (1997).
- Kansas Gas Elec. Co. v. Kodak Co., 724 F.2d 1343, 1348 (Fed. Cir. 1984).
This summary provides a detailed yet concise analysis of the litigation between Supernus Pharmaceuticals and TWI Pharmaceuticals, offering essential insights for stakeholders in pharmaceutical patent law and intellectual property management.
